Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Gains from Sales and Divestitures (2021 - 2025)

Historic Gains from Sales and Divestitures for LifeStance Health (LFST) over the last 5 years, with Q3 2025 value amounting to $6.5 million.

  • LifeStance Health's Gains from Sales and Divestitures fell 822.34% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 822.34%. This contributed to the annual value of $7221.0 for FY2024, which is 2190.98% down from last year.
  • Latest data reveals that LifeStance Health reported Gains from Sales and Divestitures of $6.5 million as of Q3 2025, which was down 822.34% from $6.4 million recorded in Q2 2025.
  • LifeStance Health's Gains from Sales and Divestitures' 5-year high stood at $7.1 million during Q3 2024, with a 5-year trough of $1711.0 in Q1 2023.
  • Over the past 5 years, LifeStance Health's median Gains from Sales and Divestitures value was $9247.0 (recorded in 2023), while the average stood at $2.3 million.
  • Per our database at Business Quant, LifeStance Health's Gains from Sales and Divestitures plummeted by 9915.71% in 2023 and then skyrocketed by 33227872.59% in 2024.
  • LifeStance Health's Gains from Sales and Divestitures (Quarter) stood at $7265.0 in 2021, then decreased by 12.7% to $6342.0 in 2022, then soared by 45.81% to $9247.0 in 2023, then dropped by 21.91% to $7221.0 in 2024, then soared by 90469.17% to $6.5 million in 2025.
  • Its Gains from Sales and Divestitures was $6.5 million in Q3 2025, compared to $6.4 million in Q2 2025 and $6.1 million in Q1 2025.